News articles about Eli Lilly and (NYSE:LLY) have trended somewhat positive on Monday, Accern reports. Accern ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Eli Lilly and earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.5758219005182 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the headlines that may have impacted Accern Sentiment’s scoring:

Eli Lilly and (NYSE:LLY) traded up 0.42% during midday trading on Monday, hitting $81.49. The stock had a trading volume of 1,879,619 shares. The company has a 50-day moving average price of $82.84 and a 200-day moving average price of $81.87. The stock has a market cap of $85.97 billion, a P/E ratio of 35.26 and a beta of 0.34. Eli Lilly and has a 52 week low of $64.18 and a 52 week high of $86.72.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.06. The firm had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The business’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.86 EPS. Equities analysts expect that Eli Lilly and will post $4.16 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th will be paid a $0.52 dividend. The ex-dividend date of this dividend is Friday, August 11th. This represents a $2.08 dividend on an annualized basis and a yield of 2.55%. Eli Lilly and’s dividend payout ratio (DPR) is presently 90.04%.

LLY has been the subject of several research reports. UBS AG cut shares of Eli Lilly and to a “hold” rating and set a $85.00 price target for the company. in a research note on Wednesday, July 26th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $100.00 price target on shares of Eli Lilly and in a research note on Monday, April 17th. Argus cut shares of Eli Lilly and from a “buy” rating to a “hold” rating and raised their target price for the company from $64.18 to $81.00 in a research note on Thursday, April 27th. They noted that the move was a valuation call. Jefferies Group LLC reissued a “buy” rating and issued a $93.00 target price on shares of Eli Lilly and in a research note on Thursday, June 22nd. Finally, Sanford C. Bernstein reissued an “outperform” rating and issued a $88.00 target price on shares of Eli Lilly and in a research note on Sunday, May 21st. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $88.27.

TRADEMARK VIOLATION WARNING: This story was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at

In other news, insider Melissa S. Barnes sold 1,900 shares of the stock in a transaction on Monday, June 12th. The stock was sold at an average price of $80.78, for a total transaction of $153,482.00. Following the completion of the transaction, the insider now owns 14,041 shares in the company, valued at approximately $1,134,231.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 220,000 shares of the stock in a transaction on Monday, July 31st. The stock was sold at an average price of $83.09, for a total value of $18,279,800.00. Following the transaction, the insider now owns 124,049,283 shares of the company’s stock, valued at approximately $10,307,254,924.47. The disclosure for this sale can be found here. Insiders sold a total of 669,733 shares of company stock valued at $55,845,287 in the last 90 days. Corporate insiders own 0.20% of the company’s stock.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Insider Buying and Selling by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.